Neurotech International (ASX:NTI) has recently announced ground-breaking results with respect to the safety, tolerability, and efficacy of NTI164 in Autism Spectrum Disorder (ASD) patients.
Stockhead
Neurotech study says cannabis could be key to helping kids on the spectrum reach potential
Neurotech International (ASX:NTI) has released promising results from a Phase I/II clinical study of its proprietary NTI164 cannabis strain in paediatric Autism Spectrum Disorder (ASD).
Neurotech tackles the anguish of autism with low-THC cannabis treatment
A medical dilemma in its own right – the modern treatment of the condition commonly known as ‘autism’ can come at a high cost and with debilitating side effects – something ASX-listed Neurotech International aims to change.
Weed Week: Cannabis-feed for chickens and cannabis campaigner nabs Queen’s Birthday honour
The company recently reported significant development in the preclinical research of its lead asset program, NTI164 – a proprietary cannabis strain that contains high levels of unique minor cannabinoids and less than 0.3% THC, exclusively licensed from Dolce Cann Global.
ASX Health Stocks: Neurotech says its cannabis strain works well when combined with Diclofenac
Neurotech International (ASX:NTI) has today reported significant development in the preclinical research of its lead asset program, NTI164.
Neurotech just started world’s first THC-less cannabis study in autistic children
The Phase I/II clinical trial announced today is a groundbreaking study where medicinal cannabis containing little to no THC is being tested on autistic children.